The era of individualized medicine has arrived in ophthalmology through genetics, biomarkers, and personalized eye care. By decoding patient-specific genetic profiles, clinicians can now identify inherited risk for eye diseases such as Leber congenital amaurosis, primary congenital glaucoma, or AMD. Biomarkers, whether molecular or imaging-based, provide additional layers of prognostic data and guide treatment selection. Personalized care means shifting from reactive to predictive strategies—intervening before irreversible damage occurs. The field is also advancing gene therapy and targeted biologics, which offer hope for previously untreatable conditions. Ethical considerations around genetic counseling and data privacy continue to evolve alongside scientific innovation. As new therapies emerge from clinical trials, precision medicine will reshape how patients are screened, monitored, and treated in everyday practice.
Title : Rare and interesting case of Goldenhar’s syndrome in a 3 years old male child
Gowhar Ahmad, Florence Hospital Srinagar, India
Title : Management of common vitreoretinal lesions: An overview and update
Tim Jackson, King’s College London, United Kingdom
Title : Targeting immunological pathways in Behcet's uveitis
Hashim Butt, Bolton Royal Hospital, United Kingdom
Title : Lumevoq gene therapy in leber hereditary optic neuropathy
Magali Taiel, GenSight Biologics, France
Title : The effect of low hypermetropia correction and office-based orthoptic training on binocular vision parameters in children with convergence insufficiency
Agnieszka Rosa, Orticus Center for the Treatment of Strabismus and Vision Disorders, Poland
Title : Evaluating the quality and readability of AI chatbot responses to frequently asked questions on basal cell carcinoma: Implications for patient education and digital health communication
Arrane Selvamogan, Leicestershire Partnership NHS Trust, United Kingdom